Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss from operations	$ (40,429,571)	$ (30,293,090)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and debt issuance costs		6,079,690
Change in fair value of warrants and embedded derivative	1,870,923	1,161,518
Non-cash interest expense on convertible bridge notes		1,045,000
Stock/unit-based compensation	6,458,115	278,365
Depreciation and amortization	41,727	22,587
Amortization of investment bond premium/(discount)	(240,620)	1,832
Net loss on settlement of convertible bridge note		3,868,771
Other		(142,510)
Changes in operating assets and liabilities:
Accounts receivable, net	(124,104)	(183,228)
Inventories	(796,445)	(329,745)
Prepaid expenses and other current assets	(2,555,468)	(232,275)
Accounts payable and accrued expenses	887,399	1,454,060
Deferred rent	(44,389)	(35,077)
Net cash used in operating activities	(34,932,433)	(17,304,102)
Cash flows from investing activities:
Purchase of debt securities and other investments available for sale	(56,589,240)	(11,211,250)
Proceeds from maturities of debt securities and other investments available for sale	26,509,684	1,000,000
Purchases of property and equipment	(278,921)	(79,527)
Net cash used in investing activities	(30,358,477)	(10,290,777)
Cash flows from financing activities:
Sale of common stock, net of related expenses	78,379,457
Proceeds from issuance of Series B Preferred Units		19,965,091
Financing costs related to the issuance of Series B Preferred Units		(1,170,949)
Proceeds from issuance of convertible bridge notes		18,707,299
Financing costs related to issuance of convertible bridge notes		(797,645)
Net cash provided by financing activities	78,379,457	36,703,796
Effect of changes in exchange rates on cash and cash equivalents	(49,004)	(138,246)
Net increase in cash and cash equivalents	13,039,543	8,970,671
Cash and cash equivalents – beginning of period	13,224,194	416,336
Cash and cash equivalents – end of period	26,263,737	9,387,007
Supplemental schedule of noncash financing activity:
Reclass of warrant liability to additional paid in capital	4,110,467
Reclass of deferred financing costs to additional paid in capital	856,985
Deferred financing costs included in accounts payable and accrued expenses		234,339
Stock dividend distribution in connection with IPO	3,629,092
Common units issued		5,194,081
Conversion of convertible bridge notes, including accrued interest, to Series B Preferred Units		26,717,909
Series B warrants issued in connection with convertible bridge notes		2,620,681
Elimination of Liquidation Preference
Supplemental schedule of noncash financing activity:
Common units issued		16,430,086
Conversion of Series B Preferred Units
Supplemental schedule of noncash financing activity:
Common units issued		4,074,447
Common warrants issued in connection with Series B financing		$ 188,944
Series A Preferred Units
Supplemental schedule of noncash financing activity:
Equity converted to common stock	53,518,463
Series B Preferred Units
Supplemental schedule of noncash financing activity:
Equity converted to common stock	68,755,544
Common Units
Supplemental schedule of noncash financing activity:
Equity converted to common stock	$ 40,180,619